Clinical trial · Observational
Use of Plasma ctDNA Methylation Haplotypes in Detecting Local Residual or Lymph Node Metastasis
Use of Plasma ctDNA Methylation Haplotypes in Detecting Local Residual or Lymph Node Metastasis: a Prospective, Clinical Study
NCT03868215CI-TRIAL-00037536unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, clinical study. This study is to evaluate the sensitivity of plasma ctDNA methylation haplotypes in detecting local residual or lymph node metastasis.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Lymph Node Metastases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Next-generation sequencing (NGS) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with endoscopically removed malignant polyps
- description
- Patients with endoscopically removed malignant polyps
- interventionNames
- Diagnostic Test: Next-generation sequencing (NGS)
Primary outcomes (1)
- measure
- Sensitivity
- timeFrame
- 2 years
- description
- The sensitivity of plasma ctDNA methylation haplotypes in detecting local residual or lymph node metastasis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with endoscopically removed malignant polyps. * Male or female ≥ 18 years of age on the day of signing informed consent. * Patients who received surgical resection following removal of malignant polyps by colonoscopy. * Patients must have a performance status of ≤1 on the ECOG Performance Scale. * Written informed consent must be obtained from patient or patient's legal representative and ability for patient to comply with the requirements of the study Exclusion Criteria: * Patients received adjuvant treatment prior to the surgical resection. * Patients received blood transfusion two weeks before or during the surgical resection. * Patients with unresected advanced colorectal adenoma. * Patients who are positive for Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C. * Patients who are pregnant. * Patients who are alcoholic or drug abusers. * Patients with a history or current evidence of any condition or abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the Investigator.
References
Publications (0)
Data not yet available
No reference posted for this study.